Literature DB >> 8961057

Penetration of vancomycin into human lung tissue.

M Cruciani1, G Gatti, L Lazzarini, G Furlan, G Broccali, M Malena, C Franchini, E Concia.   

Abstract

Vancomycin penetration into lung tissue was evaluated in thirty patients following the administration of 1 g of vancomycin as a 1 h i.v. infusion. Mean concentrations (range) of vancomycin in lung tissue were 9.6 (6.3-12.1) mg/kg at 1h, 5.7 (4.7-7.4) mg/kg at 2 h, 4.2 (0.8-6.5) mg/kg at 3-4 h, 2.4 (1.4-4.7) mg/kg at 6 h, and 2.8 (0.9-7.8) mg/kg at 12 h after the end of infusion. Ratios of lung tissue to serum concentration ranged 0.24 to 0.41 at 1 and 12 h, respectively. One of six patients observed at 6 h, and 3 of 7 patients at 12 h did not have detectable levels of vancomycin in lung tissue. A 1 h iv infusion of a 1 g dose of vancomycin does not achieve sustained lung concentrations above the MIC for susceptible staphylococci over a dosing interval of 12 h. Therefore, a more appropriate modality of administration, such as continuous infusion, should be considered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961057     DOI: 10.1093/jac/38.5.865

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  59 in total

1.  Linezolid in VAP by MRSA: a better choice?

Authors:  Malina Ioanas; Hartmut Lode
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

2.  Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.

Authors:  D D Yeh; M E Kutcher; K Lunghi
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-15       Impact factor: 3.693

Review 3.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

Review 4.  Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

5.  Current treatment of severe sepsis.

Authors:  Ismail Cinel; R Phillip Dellinger
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

6.  Prognostic assessment will be important in flu pandemic.

Authors:  Gavin D Barlow
Journal:  BMJ       Date:  2006-02-25

7.  Current problems in the diagnosis and treatment of hospital-acquired methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Masahiro Sakaguchi; Nobuaki Shime; Naohisa Fujita; Sakiko Fujiki; Satoru Hashimoto
Journal:  J Anesth       Date:  2008-05-25       Impact factor: 2.078

Review 8.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

Review 9.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  Evaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients.

Authors:  Erin J McDade; Jennifer L Hewlett; Siby P Moonnumakal; Carol J Baker
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.